232 related articles for article (PubMed ID: 19858383)
1. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.
Movsas B; Moughan J; Sarna L; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Wasserman T; Bruner DW
J Clin Oncol; 2009 Dec; 27(34):5816-22. PubMed ID: 19858383
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
3. The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.
Lawrence YR; Paulus R; Langer C; Werner-Wasik M; Buyyounouski MK; Komaki R; Machtay M; Smith C; Axelrod RS; Wasserman T; Bradley JD; Movsas B
Lung Cancer; 2013 Jun; 80(3):298-305. PubMed ID: 23477890
[TBL] [Abstract][Full Text] [Related]
4. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.
Sarna L; Swann S; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Byhardt R; Wasserman T; Movsas B
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1378-84. PubMed ID: 18501528
[TBL] [Abstract][Full Text] [Related]
5. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
[TBL] [Abstract][Full Text] [Related]
6. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.
Bragstad S; Flatebø M; Natvig GK; Eide GE; Skeie GO; Behbahani M; Pedersen PH; Enger PØ; Skeie BS
J Neurosurg; 2018 Jul; 129(1):71-83. PubMed ID: 28820304
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer.
Qi Y; Schild SE; Mandrekar SJ; Tan AD; Krook JE; Rowland KM; Garces YI; Soori GS; Adjei AA; Sloan JA
J Thorac Oncol; 2009 Sep; 4(9):1075-82. PubMed ID: 19546817
[TBL] [Abstract][Full Text] [Related]
9. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
Carey MS; Bacon M; Tu D; Butler L; Bezjak A; Stuart GC
Gynecol Oncol; 2008 Jan; 108(1):100-5. PubMed ID: 17920108
[TBL] [Abstract][Full Text] [Related]
10. Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study.
Hechtner M; Eichler M; Wehler B; Buhl R; Sebastian M; Stratmann J; Schmidberger H; Gohrbandt B; Peuser J; Kortsik C; Nestle U; Wiesemann S; Wirtz H; Wehler T; Bals R; Blettner M; Singer S
J Thorac Oncol; 2019 Mar; 14(3):420-435. PubMed ID: 30508641
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
12. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
13. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Machtay M; Bae K; Movsas B; Paulus R; Gore EM; Komaki R; Albain K; Sause WT; Curran WJ
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):425-34. PubMed ID: 20980108
[TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy.
Langendijk H; Aaronson NK; de Jong JM; ten Velde GP; Muller MJ; Wouters M
Radiother Oncol; 2000 Apr; 55(1):19-25. PubMed ID: 10788684
[TBL] [Abstract][Full Text] [Related]
15. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
[TBL] [Abstract][Full Text] [Related]
16. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
[TBL] [Abstract][Full Text] [Related]
18. The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry.
Husson O; de Rooij BH; Kieffer J; Oerlemans S; Mols F; Aaronson NK; van der Graaf WTA; van de Poll-Franse LV
Oncologist; 2020 Apr; 25(4):e722-e732. PubMed ID: 32297435
[TBL] [Abstract][Full Text] [Related]
19. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group.
Firat S; Byhardt RW; Gore E
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):357-64. PubMed ID: 12243808
[TBL] [Abstract][Full Text] [Related]
20. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.
J Natl Cancer Inst; 1999 Jan; 91(1):66-72. PubMed ID: 9890172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
